1. Introduction {#sec1}
===============

Mitochondrial diabetes, which is known as a maternally transmitted clinical subtype of diabetes, is most commonly caused by an A to G substitution in the mitochondrial DNA at position 3243 (mt3243A \> G mutation), which encodes tRNALeu(UUR) \[[@B1]\]. Since it was first identified in 1990, the mt3243A \> G mutation has been well investigated in many ethnic groups \[[@B2]--[@B6]\]. The reported prevalence of the mt3243A \> G mutation varies from study to study, largely due to different races of patients and the selection criteria \[[@B7]--[@B11]\]. The prevalence of the mt3243A \> G mutation among patients with type 2 diabetes (T2DM) in China and Finland is 0.4% and 1.0%, respectively \[[@B8], [@B12]\]. This prevalence increases to 5.9% in early onset patients with a family history of diabetes and reaches 60% in patients with both T2DM and deafness \[[@B5], [@B11]\].

On the other hand, the clinical phenotype of the mt3243A \> G mutation is variable, partially due to the number of affected mitochondria in different tissues. This characteristic is referred to as heteroplasmy. Levels of heteroplasmy can vary between tissues and even within one tissue in a single patient over time \[[@B1]\]. In previous studies, DNA extracted from peripheral blood samples was screened using PCR restriction fragment length polymorphism (PCR-RFLP) analysis and Sanger sequencing \[[@B1]\]. However, other studies, including our own, have demonstrated that heteroplasmy is lower in peripheral blood than in urine sediment, suggesting that the detection rate could be improved by using urine sediment \[[@B13]--[@B16]\]. In addition, our previous study also showed that high-resolution melting (HRM) curve analysis is a rapid and sensitive method to screen for this mutation in urine sediment. Samples from mt3243A \> G mutation carriers were differentiated by distinct melting curves in HRM, and subsequent pyrosequencing validated positive samples and quantified the level of heteroplasmy. In contrast, the level of heteroplasmy could not be quantified by Sanger sequencing, as the peak height was not proportional to the degree of heteroplasmy \[[@B16]\]. Therefore, the implementation of a noninvasive diagnostic method to detect the mt3243A \> G mutation in urine sediment by HRM analysis combined with pyrosequencing is expected to detect more patients carrying the mt3243A \> G mutation.

In this study, we aimed to identify mt3243A \> G mutation carriers in urine sediment samples from a group of elderly Chinese type 2 diabetic patients.

2. Materials and Methods {#sec2}
========================

2.1. Subjects {#sec2.1}
-------------

Data were obtained from a community-based peer-education project conducted between January 2013 and December 2015. A total of 1041 patients with T2DM who completed a baseline questionnaire were enrolled in this study. The mean age at recruitment and age at diagnosis of the cohort was 67.2 ± 6.7 years and 54.8 ± 8.1 years, respectively. Body mass index (BMI) was calculated as weight in kilograms divided by height in metres squared. The diagnosis of diabetes was confirmed according to the 1999 World Health Organization (WHO) criteria \[[@B17]\]. The study was approved by the Institutional Review Board of Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital and conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from each participant.

2.2. DNA Samples {#sec2.2}
----------------

Urine sediment samples were collected from 1041 patients. Blood, saliva, and urine sediment samples were collected from patients who were identified as carrying the mt3243A \> G mutation and from their family members. DNA was extracted and purified using an automated nucleic acid extraction instrument (Lab-Aid 820; BioV, China). The eluted DNA concentration was measured using a NanoDrop spectrophotometer, and the DNA was diluted to 10 ng/μl.

2.3. High Resolution Melting Curve (HRM) Analysis {#sec2.3}
-------------------------------------------------

PCR reactions were performed in a Rapid Cycler (Idaho Technology, Salt Lake City, UT) using the primers MT3243-F (5′-TTCACAAAGCGCCTTCCCCC-3′) and MT3243-R (5′-CCATTGCGATTAGAATGGGTACA-3′). Screening of the mt3243A \> G mutation was undertaken on PCR products using HRM analysis (Idaho Technology). Melting was conducted from 75°C to 95°C at 0.3°C per second. The melting curves were analysed by the software, with normalized curves for comparison among samples.

2.4. Pyrosequencing {#sec2.4}
-------------------

PCR products from patients carrying the mt3243A \> G mutation detected by HRM analysis were analysed using pyrosequencing according to the previous report \[[@B16]\].

2.5. Clinical Evaluation of Patients with the mt3243A \> G Mutation {#sec2.5}
-------------------------------------------------------------------

Information about patients with the mt3243A \> G mutation was obtained by a standard questionnaire and a face-to-face interview. Laboratory examinations included routine urine and blood tests, HbA1c, fasting plasma glucose, 2 h postprandial plasma glucose, fasting C-peptide, 2 h postprandial C-peptide, glutamic acid decarboxylase (GAD-Ab), islet antigen 2 (IA2-Ab), cardiac enzyme, lipid profile, liver and renal biochemistry profile, and electrolyte profile.

Audiometric, ophthalmologic, neurological, and cardiac examinations were performed to assess the effect of the mt3243 A \> G mutation on multiorgan involvement. Diagnosis of hearing loss was based on audiometric measurements, including air-conduction pure-tone thresholds, bone-conduction thresholds, tympanometry, and distortion-product otoacoustic emission (DPOAE). A standardized ophthalmologic examination was performed including best-corrected visual acuity of both eyes, ophthalmoscopy after pupillary dilation, fundus photograph electrooculogram (EOG), flash electroretinogram (FERG), multifocal ERG (mfERG), and optical coherence tomography scans (OCT) to give insight into the current functional status of the patient. To evaluate neurological function, a neurologic physical examination, electromyography (EMG), electroencephalogram (EEG), and brain magnetic resonance imaging (MRI) were performed. To evaluate cardiac function, electrocardiogram (EKG) and echocardiography were conducted.

2.6. Statistical Methods {#sec2.6}
------------------------

Characteristics of participants were presented by descriptive statistics. Data were analysed using SPSS version 21.0 (SPSS Inc., Chicago, IL) and expressed as the mean ± SD for continuous variables.

3. Results {#sec3}
==========

3.1. Screening for Mutation in the Studied Population {#sec3.1}
-----------------------------------------------------

The clinical characteristics of patients with T2DM are summarized in [Table 1](#tab1){ref-type="table"}. By comparing the melting curves of patients to healthy controls, two patients (2/1041) carrying the mt3243A \> G mutation were detected among all patients with T2DM. In addition, quantification of the heteroplasmy of the mutation in the two patients was further analysed by pyrosequencing with DNA from peripheral blood leukocytes, saliva, and urine sediment samples. The measured heteroplasmy was adjusted by a cubic polynomial curve according to our previous study \[[@B16]\]. In patient 1, the heteroplasmy was 0.8%, 2.8%, and 14.7% in peripheral blood leukocytes, saliva, and urine sediment, respectively. In patient 2, the heteroplasmy was 5.3%, 8.4%, and 37.7% in peripheral blood leukocytes, saliva, and urine sediment, respectively.

3.2. Clinical Case Presentation {#sec3.2}
-------------------------------

Patient 1 (F1955II-1) was a 74-year-old man who had been diagnosed with T2DM at the age of 56 ([Table 2](#tab2){ref-type="table"}). He had been treated with metformin for 18 years until he was identified as carrying the mt3243A \> G mutation in this study. His BMI was 23.7 kg/m^2^. He had lower levels of LDL-c and fasting C-peptide. The patient had never undergone any episodes of hypoglycaemia, diabetic ketoacidosis, or lactic acidosis.

In this study, the patient had newly diagnosed bilateral sensorineural hearing loss at all frequencies according to the results of the audiogram ([Figure 1](#fig1){ref-type="fig"}). Best-corrected visual acuity (BCVA) was 20/25 bilateral. Fundus photograph showed no obvious diabetic retinopathy. Optical coherence tomography (OCT) image of the right eye was normal; however, a drusen-like hyperreflective lesion was found in the left eye on OCT image. This dome-shaped change was likely to originate from the retinal pigment epithelium (RPE), which induced IS/OS disruption. In addition, ophthalmic electrophysiology was performed to detect the visual function. Bilateral eyes had normal function of electrooculogram (EOG), while flash electroretinogram (FERG) suggested a decrease of b wave in bright adaption. Furthermore, multifocal ERG (mfERG) showed a decrease of amplitudes bilateral. Hypomnesia was present from the age of 56. The main findings of the MRI were hypointensity on T1-weighted images and hyperintensity on T2-weighted images of the bilateral frontal lobe, bilateral parietal lobe, basal ganglia and corona radiata, indicating cerebral ischaemia, lacunar infarction, and cerebral atrophy. Echocardiography showed tricuspid and aortic regurgitation, though the patient\'s blood pressure was normal. One of his siblings (F1955II-2) was also found to carry the mt3243A \> G mutation and presented with hearing loss without being exposed to noise. Patient F1955II-2 was diagnosed with diabetes at the age of 55. The patient\'s parents were deceased, and their medical history of diabetes and the mt3243A \> G mutation were not available ([Figure 2](#fig2){ref-type="fig"}).

Patient 2 (F1956II-1) was a 72-year-old man diagnosed with T2DM at the age of 57 ([Table 2](#tab2){ref-type="table"}). Clinical examination results, including audiogram, were not available as a result of the patient\'s severe lower limb fractures. He had been treated with metformin for 15 years until he was identified as carrying the mt3243A \> G mutation in this study. He had higher levels of HbA1c (7.9%) and 2 h postprandial plasma glucose level (12.40 mmol/L). His BMI was 19.2 kg/m^2^. Self-reported hearing loss was present since the age of 50 without being exposed to noise, and the patient reported the development of blurred vision at the age of 62. Genetic testing of his family members revealed that none of them carried the mt3243A \> G mutation. The patient\'s parents were deceased, and their medical histories of diabetes and the mt3243A \> G mutation were not available ([Figure 2](#fig2){ref-type="fig"}).

4. Discussion {#sec4}
=============

In this study, we screened for the mt3243A \> G mutation in urine sediments of elderly Chinese T2DM patients using HRM analysis combined with pyrosequencing. We found that the occurrence of the mt3243A \> G mutation was 0.2% (2 of 1041 patients) in elderly Chinese T2DM patients. The occurrence of this mutation (0.2%) in elderly T2DM patients (ages ranging from 47 to 85 years) was similar to that observed in unrelated non-insulin-dependent diabetes mellitus (NIDDM) patients (0.3%, ages ranging from 8 to 58 years) \[[@B5]\]. Because metformin can increase the risk of lactate acidosis in T2DM patients with the mt3243A \> G mutation, it is worthwhile screening for this mutation before treatment despite its low occurrence in elderly T2DM patients.

The most common genetic methods for the detection and quantitation of the mt3243A \> G mutation in previous studies were PCR-RFLP and Sanger sequencing, and peripheral blood was the most common source of material for genetic screening. However, the level of heteroplasmy in peripheral blood is much lower than that in urine sediment and tends to decline over time \[[@B13]--[@B16]\]. Thus, urine sediment is an ideal choice of material for screening for the mt3243A \> G mutation in elderly patients. On the other hand, PCR-RFLP analysis and Sanger sequencing are often used to detect the mt3243 A \> G mutation. However, Yan et al. reported that PCR-RFLP and Sanger sequencing only detect the mt3243A \> G mutation when the level of heteroplasmy is more than 5--10%, while the sensitivity of HRM (2%) is much higher \[[@B16], [@B18]\]. Moreover, pyrosequencing can accurately quantify the level of heteroplasmy from 0% to 100% \[[@B16]\]. Our study confirms the feasibility of screening for the mt3243 A \> G mutation in urine sediment by HRM followed by pyrosequencing in an elderly T2DM cohort. Consistent with previous studies, the results of this study showed that the heteroplasmy of both patients carrying the mt3243 A \> G mutation increased from peripheral blood leukocytes to urine sediment \[[@B13], [@B14]\].

It is well known that patients with the mt3243 A \> G mutation have a wide variety of disease manifestations. In this study, audiometric, ophthalmologic, neurological, and cardiac examinations were performed to assess the effects of the mt3243A \> G mutation on multiple organs. Both of the two patients showed hearing loss. Patient 1 had characteristic bilateral sensorineural hearing loss at all frequencies and patient 2 showed self-reported hearing loss, which is consistent with previous studies showing that approximately more than half of diabetic patients carrying this mutation have sensorineural hearing loss \[[@B19]\]. For the eyes, mfERG indicated foveal photoreceptor dysfunction bilaterally while RPE function had no obvious abnormality from EOG examination. However, OCT scanning showed a drusen-like hyperreflective lesion in the left eye. This dome-shaped change was likely to originate from RPE. These findings imply that foveal photoreceptors might have dysfunction accompanied with or without RPE abnormality in mt3243 A \> G mutation carriers as previously reported \[[@B20], [@B21]\]. Even in the absence of stroke-like episodes, MRI of patient 1 showed widespread hyperintensity on T2-weighted images of the bilateral frontal lobe, bilateral parietal lobe, basal ganglia, and corona radiata, indicating cerebral ischaemia, lacunar infarction, and cerebral atrophy. Interestingly, previous studies also reported hyperintensity of the bilateral basal ganglia and corona radiata on T2-weighted images in mt3243A \> G mutation carriers, either with or without mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome \[[@B22]--[@B24]\]. Further research is warranted to investigate the relationship between T2-weighted images and the mt3243A \> G mutation.

In conclusion, our study found that the occurrence of the mt3243A \> G mutation was 0.2% in elderly Chinese T2DM patients. Furthermore, screening for the mt3243A \> G mutation in urine sediment using HRM and pyrosequencing can make a rapid and accurate etiological diagnosis possible and thus contributes to precision and personalized medicine.
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![Bilateral pure-tone audiometry in patient 1. An ear hearing level equals or less than 25 dB was considered normal.](JDR2017-4683857.001){#fig1}

![Pedigree of two families with mt3243A \> G mutation (F1955 and F1956). ○ = female; □ = male; ![](JDR2017-4683857.i001.jpg), ▨ = patients with mt3243A \> G mutation; Ø, ![](JDR2017-4683857.i002.jpg) = deceased. The arrow indicates the probands. Present age, age of diagnosis, and hearing loss are also shown.](JDR2017-4683857.002){#fig2}

###### 

The clinical characteristics of patients with type 2 diabetes.

  Clinical characteristics   Diabetic subjects (*n* = 1041)
  -------------------------- --------------------------------
  Age                        67.2 ± 6.7
  Age of diagnosis (years)   54.8 ± 8.1
  Male (%)                   36.2
  BMI (kg/m^2^)              26.3 ± 5.0
  HbA1c (%)                  7.2 ± 1.3

BMI denotes body mass index.

###### 

The biochemical and clinical characteristics of two patients with T2DM carrying the mt3243 A \> G mutation.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical and biochemical characteristics   Patient 1\                                                                                                                                                               Patient 2\
                                             (F1955II-1)                                                                                                                                                              (F1956II-1)
  ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------
  Age (years)                                74                                                                                                                                                                       72

  Age of diagnosis (years)                   56                                                                                                                                                                       57

  Sex (M/F)                                  M                                                                                                                                                                        M

  BMI (kg/m^2^)                              23.7                                                                                                                                                                     19.5

  Blood pressure (mmHg)                                                                                                                                                                                               

   SBP                                       124                                                                                                                                                                      108

   DBP                                       68                                                                                                                                                                       68

  HbA1c (%)                                  5.9                                                                                                                                                                      7.9

  Fasting plasma glucose (mmol/L)            5.24                                                                                                                                                                     6.92

  2 h postprandial plasma glucose (mmol/L)   10.25                                                                                                                                                                    12.40

  Fasting C-peptide (ng/mL)                  0.64                                                                                                                                                                     1.21

  2 h postprandial C-peptide (ng/mL)         2.30                                                                                                                                                                     2.89

  GAD-Ab (U/mL)                              0.00                                                                                                                                                                     0.00

  IA2-Ab (U/mL)                              0.00                                                                                                                                                                     0.00

  Triglyceride (mmol/L)                      0.61                                                                                                                                                                     1.09

  Total cholesterol (mmol/L)                 3.48                                                                                                                                                                     4.11

  HDL-c (mmol/L)                             1.65                                                                                                                                                                     0.99

  LDL-c (mmol/L)                             1.61                                                                                                                                                                     2.50

  Urine ketones                              Negative                                                                                                                                                                 Negative

  ACR (μg/mg)                                9.23                                                                                                                                                                     152.55

  Creatinine kinase (U/L)                    104                                                                                                                                                                      22

  Treatment                                  Oral drugs, insulin                                                                                                                                                      Oral drugs

  Thyroid disease                            No                                                                                                                                                                       No

  Self-reported hearing impairment           No                                                                                                                                                                       Yes

  Audiogram                                  Bilateral sensorineural hearing loss                                                                                                                                     NA

  Neurological involvement                   Hypomnesia                                                                                                                                                               No

  MRI                                        Hypointensity on T1-weighted images and hyperintensity on T2-weighted images of the bilateral frontal lobe, bilateral parietal lobe, basal ganglia, and corona radiata   NA

  Retinal OCT                                IS/OS disruption                                                                                                                                                         NA
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI: body mass index; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; ACR: urinary albumin to creatinine ratio; GAD-Ab: glutamic acid decarboxylase (GAD-Ab); IA2-Ab: islet antigen 2 (IA2-Ab); NA: not available; OCT: optical coherence tomography; IS/OS: inner/outer segment.
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